Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
African Programme for Onchocerciasis Control 1995-2015: Model-Estimated Health Impact and Cost
PLoS Neglected Tropical Diseases, Volume 7, No. 1, Article e2032, Year 2013
Notification
URL copied to clipboard!
Description
Background: Onchocerciasis causes a considerable disease burden in Africa, mainly through skin and eye disease. Since 1995, the African Programme for Onchocerciasis Control (APOC) has coordinated annual mass treatment with ivermectin in 16 countries. In this study, we estimate the health impact of APOC and the associated costs from a program perspective up to 2010 and provide expected trends up to 2015. Methods and Findings: With data on pre-control prevalence of infection and population coverage of mass treatment, we simulated trends in infection, blindness, visual impairment, and severe itch using the micro-simulation model ONCHOSIM, and estimated disability-adjusted life years (DALYs) lost due to onchocerciasis. We assessed financial costs for APOC, beneficiary governments, and non-governmental development organizations, excluding cost of donated drugs. We estimated that between 1995 and 2010, mass treatment with ivermectin averted 8.2 million DALYs due to onchocerciasis in APOC areas, at a nominal cost of about US$257 million. We expect that APOC will avert another 9.2 million DALYs between 2011 and 2015, at a nominal cost of US$221 million. Conclusions: Our simulations suggest that APOC has had a remarkable impact on population health in Africa between 1995 and 2010. This health impact is predicted to double during the subsequent five years of the program, through to 2015. APOC is a highly cost-effective public health program. Given the anticipated elimination of onchocerciasis from some APOC areas, we expect even more health gains and a more favorable cost-effectiveness of mass treatment with ivermectin in the near future. © 2013 Coffeng et al.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC3561133/bin/pntd.0002032.s001.pdf
Authors & Co-Authors
Coffeng, Luc E.
Netherlands, Rotterdam
Erasmus Mc
Stolk, Wilma A.
Netherlands, Rotterdam
Erasmus Mc
Zouré, Honorat Gustave Marie
Burkina Faso, Ouagadougou
African Programme for Onchocerciasis Control
Veerman, J. Lennert
Netherlands, Rotterdam
Erasmus Mc
Australia, Brisbane
The University of Queensland
Agblewonu, Koffi B.
Burkina Faso, Ouagadougou
African Programme for Onchocerciasis Control
Murdoch, Michele E.
United Kingdom, Watford
Watford General Hospital
Noma, Mounkaïla M.
Burkina Faso, Ouagadougou
African Programme for Onchocerciasis Control
Fobi, Grace
Burkina Faso, Ouagadougou
African Programme for Onchocerciasis Control
Richardus, J. H.
Netherlands, Rotterdam
Erasmus Mc
Bundy, Donald A.P.
United States, Washington, D.c.
The World Bank, Usa
Habbema, J. Dik F.
Netherlands, Rotterdam
Erasmus Mc
de Vlas, Sake Jan
Netherlands, Rotterdam
Erasmus Mc
Amazigo, Uche V.
Burkina Faso, Ouagadougou
African Programme for Onchocerciasis Control
Nigeria, Enugu
Independent Consultant
Statistics
Citations: 123
Authors: 13
Affiliations: 6
Identifiers
Doi:
10.1371/journal.pntd.0002032
ISSN:
19352727
e-ISSN:
19352735
Research Areas
Disability
Health System And Policy
Infectious Diseases
Study Design
Cross Sectional Study